Australia markets closed

EGRX Dec 2022 60.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.32000.0000 (0.00%)
At close: 02:09PM EDT
Full screen
Previous close1.3200
Open1.3400
Bid0.0000
Ask2.4000
Strike60.00
Expiry date2022-12-16
Day's range1.3200 - 1.3400
Contract rangeN/A
Volume2
Open interest764
  • Zacks

    New Strong Sell Stocks for September 9th

    EGRX, TWTR and PLAY have been added to the Zacks Rank #5 (Strong Sell) List on September 9, 2022.

  • GlobeNewswire

    Eagle Pharmaceuticals to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

    WOODCLIFF LAKE, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the Morgan Stanley 20th Annual Global Healthcare Conference as follows: Date:September 13, 2022Time:5:15PM ETWebcast:Click here The webcast will be accessible via the Company’s website at www.eagleus.com, under the Investors section. Eagle

  • GlobeNewswire

    Federal Circuit Rules in Favor of Eagle Pharmaceuticals in Vasopressin Litigation

    WOODCLIFF LAKE, N.J., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District Court for the District of Delaware’s decision that Eagle’s vasopressin product does not infringe on any of the patents asserted by Par Pharmaceutical, Inc. (“Par”). Par previously sued Eagle in 2018, alleging infringement of several of its patents and a trial was held in July